Skip to main content
Article thumbnail
Location of Repository

The efficacy and tolerability of leflunomide (Arava®) in therapy for psoriatic arthritis

By Vladimir Vasilyevich Badokin

Abstract

<p>The paper gives data on differentiated disease-modifying anti-rheumatic therapy for psoriatic arthritis (PsA). When performing the therapy, account must be taken of the presence and magnitude of the major manifestations of this disease: the pattern of arthritis and spondylosis, the number of inflamed entheses, the number of swollen fingers or toes, the pattern of psoriasis in terms of its extent and stage, the presence and magnitude of systemic manifestations and the functional state of involved organs. There are data on the biological activity of leflunomide, its effect on the main manifestations of PsA with an analysis of its efficacy and tolerability, as well as the results of a comparative investigation of disease-modifying anti-rheumatic drugs used for the therapy of this disease.</p

Topics: псориатический артрит, базисные противовоспалительные препараты, терапия, Medicine, R
Publisher: IMA-PRESS LLC
Year: 2013
OAI identifier: oai:doaj.org/article:30b2f84de17d420d9d06755f568474b1
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2310-158X (external link)
  • https://doaj.org/toc/1996-7012 (external link)
  • http://mrj.ima-press.net/mrj/a... (external link)
  • https://doaj.org/article/30b2f... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.